ПАТОГЕНЕТИЧЕСКОЕ ЛЕЧЕНИЕ НЕПРОЛИФЕРАТИВНОЙ ДИАБЕТИЧЕСКОЙ РЕТИНОПАТИИ

Н. Р. Янгиева, Д.М. Туйчибаева, Ф. М. Урманова, С.С. Агзамова

Передовая Офтальмология · 2024-yil

Annotatsiya

Relevance. Diabetic retinopathy (DR) is one of the most common microvascular complications of diabetes mellitus (DM) and the leading cause of blindness worldwide. The effects of neurotrophins on stimulating neurogenesis and cell replacement in ischemic areas have been proven. Purpose of the study. Based on clinical, functional and biochemical parameters, to study the effectiveness of using the drug Semax in patients with non-proliferative diabetic retinopathy. Materials and methods. A total of 64 patients (128 eyes) with type 2 diabetes were examined, of which the first control group consisted of 15 patients (n=30) of the same age category andconcomitant pathology, not suffering from diabetes, the second group - 20 patients (n=40) with type 2 diabetes without signsof DR, the third group - 15 patients (n=30) with mild NPDR, the fourth group - 14 patients (n=28) with moderate NPDR. Resultsand conclusion. The studies revealed a decrease in BDNF parameters before DR occurred clinically (Group II). After the courseof treatment, an increase in BDNF parameters in the SF in Group II patients by 15% was found, above the initial level. In GroupIII, an increase in BDNF parameters by 1.3 times was noted in 86.2% of cases, above the values before treatment. An inversecorrelation was established between BDNF and CTS parameters. Analysis of the results of the study showed high efficiencyof Semax in patients with non-proliferative diabetic retinopathy.

Maqola ma’lumotlari
MualliflarН. Р. Янгиева, Д.М. Туйчибаева, Ф. М. Урманова, С.С. Агзамова
JurnalПередовая Офтальмология
Nashr sanasi2024-09-25
Jild9
Son3
Betlar81-84
Tilru
DOI10.57231/j.ao.2024.9.3.016

Передовая Офтальмология jurnalidan boshqa maqolalar

Передовая Офтальмология — barcha maqolalar